• Abreu MT, Yang H 2004 Is genetic testing in IBD ready for prime time? Am. J. Gastroenterol. 99: 316-318. *

• Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R 2004 Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351: 1972-1977. *

• Akolkar PN, Gulwani-Akolkar B, Lin XY, Zhou Z, Daly M, Katz S, Levine J, Present D, Gelb B, Desnick R, Mayer L, Silver J 2001 The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset disease. Am. J. Gastroenterol. 96: 1127-1132. *

• Alaez C, Gazit E, Ibarrola B, Yaron M, Livneh A, Avishai O, Gorodezky C 2007 Distribution of HLA-B27 subtypes in ankylosing spondylitis in an Israeli population. Arch. Med. Res. 38: 452-455.

• Arkkila PE 2006 Thromboangiitis obliterans (Buerger's disease). Orphanet J. Rare Dis. 1: 14. *

• Augarten A, Kerem BS, Yahav Y, Noiman S, Rivlin Y, Tal A, Blau H, Ben-Tur L, Szeinberg A, Kerem E, et al 1993 Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C-->T mutation. Lancet 342: 25-26.

• Avramopoulos D, Lasseter VK, Fallin MD, Wolyniec PS, McGrath JA, Nestadt G, Valle D, Pulver AE 2007 Stage II follow-up on a linkage scan for bipolar disorder in the Ashkenazim provides suggestive evidence for chromosome 12p and the GRIN2B gene. Genet. Med. 9: 745-751.

• Bach G 2005 Mucolipin 1: endocytosis and cation channel - a review. Pflugers Arch. 451: 313-317. *

• Baglioni S, Genuardi M 2004 Simple and complex genetics of colorectal cancer susceptibility. Am. J. Med. Genet. 129C: 35-43. *

• Bagnoli S, Putignano AL, Melean G, Baglioni S, Sestini R, Milla M, d'Albasio G, Genuardi M, Pacini F, Trallori G, Papi L 2004 Susceptibility to refractory ulcerative colitis is associated with polymorphism in the hMLH1 mismatch repair gene. Inflamm. Bowel Dis. 10: 705-708. *

• Barchana M, Liphshitz I, Rozen P 2004 Trends in colorectal cancer incidence and mortality in the Israeli Jewish ethnic populations. Fam. Cancer 3: 207-214. *

• Basu D, Lopez I, Kulkarni A, Sellin JH 2005 Impact of race and ethnicity on inflammatory bowel disease. Am. J. Gastroenterol. 100: 2254-2261. *

• Bergman A, Atzmon G, Ye K, Maccarthy T, Barzilai N 2007 Buffering mechanisms in aging: a systems approach toward uncovering the genetic component of aging. PLoS Comput. Biol. 3: e170. *

• Black M, Mignogna M, Scully C 2005 Pemphigus vulgaris. Oral Dis. 11: 119-130. *

• Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T, Chen FF, Foster SJ, Duerr RH, Brant SR, Cho JH, Nunez G 2003 Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124: 140-146. *

• Bonne-Tamir B, Bodmer JG, Bodmer WF, Pickbourne P, Brautbar C, Gazit E, Nevo S, Zamir R 1978 HLA polymorphism in Israel. 9. An overall comparative analysis. Tissue Antigens 11: 235-250.

• Brant SR, Fu Y, Fields CT, Baltazar R, Ravenhill G, Pickles MR, Rohal PM, Mann J, Kirschner BS, Jabs EW, Bayless TM, Hanauer SB, Cho JH 1998 American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology 115: 1056-1061. *

• Brett PM, Yiannakou JY, Morris MA, Bronson SR, Mathew C, Curtis D, Ciclitira PJ 1998 A pedigree-based linkage study of coeliac disease: failure to replicate previous positive findings. Ann. Hum. Genet. 62: 25-32. *

• Brown AM, Gordon D, Lee H, Caudy M, Hardy J, Haroutunian V, Blass JP 2004 Association of the dihydrolipoamide dehydrogenase gene with Alzheimer's disease in an Ashkenazi Jewish population. Am. J. Med. Genet. 131B: 60-66. *

• Bruck R, Ashkenazi M, Weiss S, Goldiner I, Shapiro H, Aeed H, Genina O, Helpern Z, Pines M 2007 Prevention of liver cirrhosis in rats by curcumin. Liver Int. 27: 373-383. *

• Cattan D, Notarnicola C, Molinari N, Touitou I 2000 Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. Lancet 355: 378-379. *

• Charrow J 2004 Ashkenazi Jewish genetic disorders. Fam. Cancer 3: 201-206. *

• Chermesh I, Azriel A, Alter-Koltunoff M, Eliakim R, Karban A, Levi BZ 2007 Crohn's disease and SLC11A1 promoter polymorphism. Dig. Dis. Sci. 52: 1632-1635. *

• Cho J 2000 Update on inflammatory bowel disease genetics. Curr. Gastroenterol. Rep. 2: 434-439.

• Cho JH 2001 Update on the genetics of inflammatory bowel disease. Curr. Gastroenterol. Rep. 3: 458-463.

• Cho JH, Nicolae DL, Gold LH, Fields CT, LaBuda MC, Rohal PM, Pickles MR, Qin L, Fu Y, Mann JS, Kirschner BS, Jabs EW, Weber J, Hanauer SB, Bayless TM, Brant SR 1998 Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc. Natl. Acad. Sci. U.S.A. 95: 7502-7507. *

• Ciernikova S, Tomka M, Kovac M, Stevurkova V, Zajac V 2006 Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma 53: 97-102. *

• Clark LN, Nicolai A, Afridi S, Harris J, Mejia-Santana H, Strug L, Cote LJ, Louis ED, Andrews H, Waters C, Ford B, Frucht S, Fahn S, Mayeux R, Ottman R, Marder K 2005 Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov. Disord. 20: 100-103. *

• Cohen R, Metzger S, Nahir M, Chajek-Shaul T 2002 Association of the MIC-A gene and HLA-B51 with Behcet's disease in Arabs and non-Ashkenazi Jews in Israel. Ann. Rheum. Dis. 61: 157-160. *

• Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ 1995 The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 86: 3835-3840. *

• Cox ST, Marsh SG, Scott I, Clayton J, Arguello JR, McWhinnie AJ, Prokupek B, Holman R, Madrigal JA, Little AM 1999 HLA-A, -B, -C polymorphism in a UK Ashkenazi Jewish potential bone marrow donor population. Tissue Antigens 53: 41-50. *

• Cretney E, McQualter JL, Kayagaki N, Yagita H, Bernard CC, Grewal IS, Ashkenazi A, Smyth MJ 2005 TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol. Cell Biol. 83: 511-519. *

• Dagan E, Laitman Y, Levanon N, Feuer A, Sidi AA, Baniel J, Korach Y, Baruch GB, Friedman E, Gershoni-Baruch R 2006 The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel. Fam. Cancer 5: 389-395. *

• Delatycki MB 2008 Population screening for reproductive risk for single gene disorders in Australia: now and the future. Twin Res. Hum. Genet. 11: 422-430.

• Dresner-Pollak R, Ackerman Z, Eliakim R, Karban A, Chowers Y, Fidder HH 2004 The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet. Test. 8: 417-420.

• Dror Y, Blachar Y, Cohen P, Livni N, Rosenmann E, Ashkenazi A 1998 Systemic lupus erythematosus associated with acute Epstein-Barr virus infection. Am. J. Kidney Dis. 32: 825-828.

• Duerr RH 2003 Update on the genetics of inflammatory bowel disease. J. Clin. Gastroenterol. 37: 358-367.

• Dundar M, Caglayan AO, Saatci C, Karaca H, Baskol M, Tahiri S, Ozkul Y 2007 How the I1307K adenomatous polyposis coli gene variant contributes in the assessment of risk of colorectal cancer, but not stomach cancer, in a Turkish population. Cancer Genet. Cytogenet. 177: 95-97.

• Ekstein J, Rubin BY, Anderson SL, Weinstein DA, Bach G, Abeliovich D, Webb M, Risch N 2004 Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am. J. Med. Genet. 129A: 162-164. *

• El-Shanti H, Majeed HA, El-Khateeb M 2006 Familial Mediterranean fever in Arabs. Lancet 367: 1016-1024. *

• Esters N, Pierik M, van Steen K, Vermeire S, Claessens G, Joossens S, Vlietinck R, Rutgeerts P 2004 Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am. J. Gastroenterol. 99: 299-305. *

• Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, Steel G, Nestadt G, Liang KY, Huganir RL, Valle D, Pulver AE 2005 Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am. J. Hum. Genet. 77: 918-936. *

• Fidder H, Chowers Y, Ackerman Z, Pollak RD, Crusius JB, Livneh A, Bar-Meir S, Avidan B, Shinhar Y 2005 The familial Mediterranean fever (MEVF) gene as a modifier of Crohn's disease. Am. J. Gastroenterol. 100: 338-343. *

• Fidder HH, Figer A, Geva R, Flex D, Schayek H, Avidan B, Meir SB, Friedman E 2005 Genetic analyses in consecutive Israeli Jewish colorectal cancer patients. Am. J. Gastroenterol. 100: 1376-1380. *

• Fidder HH, Heijmans R, Chowers Y, Bar-Meir S, Avidan B, Pena AS, Crusius JB 2006 TNF-857 polymorphism in Israeli Jewish patients with inflammatory bowel disease. Int. J. Immunogenet. 33: 81-85. *

• Fidder HH, Olschwang S, Avidan B, Zouali H, Lang A, Bardan E, Picard O, Bar-Meir S, Colombel JF, Chowers Y 2003 Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients. Am. J. Med. Genet. 121A: 240-244. *

• Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A, Friedman E 2001 The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br. J. Cancer 84: 478-481. *

• Fischer M, Wetherill LF, Carr LG, You M, Crabb DW 2007 Association of the aldehyde dehydrogenase 2 promoter polymorphism with alcohol consumption and reactions in an American Jewish population. Alcohol Clin. Exp. Res. 31: 1654-1659. *

• Foulkes WD, Thiffault I, Gruber SB, Horwitz M, Hamel N, Lee C, Shia J, Markowitz A, Figer A, Friedman E, Farber D, Greenwood CM, Bonner JD, Nafa K, Walsh T, Marcus V, Tomsho L, Gebert J, Macrae FA, Gaff CL, Paillerets BB, Gregersen PK, Weitzel JN, et al 2002 The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am. J. Hum. Genet. 71: 1395-1412. *

• Gao XJ, Brautbar C, Gazit E, Segal R, Naparstek Y, Livneh A, Stastny P 1991 A variant of HLA-DR4 determines susceptibility to rheumatoid arthritis in a subset of Israeli Jews. Arthritis Rheum. 34: 547-551.

• Gilat T, Rozen P 1979 Epidemiology of Crohn's disease and ulcerative colitis: etiologic implications. Isr. J. Med. Sci. 15: 305-308.

• Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, Friedman E, Narod S, Olshen AB, Gregersen P, Kosarin K, Olsh A, Bergeron J, Ellis NA, Klein RJ, Clark AG, Norton L, Dean M, Boyd J, Offit K 2008 Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl. Acad. Sci. U.S.A. 105: 4340-4345. *

• Grossman I, Avidan N, Singer C, Paperna T, Lancet D, Beckmann JS, Miller A 2004 Genomic profiling of interpopulation diversity guides prioritization of candidate-genes for autoimmunity. Genes Immun. 5: 493-504.

• Guillem JG, Moore HG, Palmer C, Glogowski E, Finch R, Nafa K, Markowitz AJ, Offit K, Ellis NA 2004 A636P testing in Ashkenazi Jews. Fam. Cancer 3: 223-227. *

• Gulwani-Akolkar B, Akolkar PN, Lin XY, Heresbach D, Manji R, Katz S, Yang SY, Silver J 2000 HLA class II alleles associated with susceptibility and resistance to Crohn's disease in the Jewish population. Inflamm. Bowel Dis. 6: 71-76. *

• Hanauer SB 2006 Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 12 Suppl. 1: S3-S9. *

• Hansen SK, Rose CS, Glumer C, Drivsholm T, Borch-Johnsen K, Jorgensen T, Pedersen O, Hansen T 2005 Variation near the hepatocyte nuclear factor (HNF)-4alpha gene associates with type 2 diabetes in the Danish population. Diabetologia 48: 452-458. *

• Hasin Y, Avidan N, Bercovich D, Korczyn A, Silman I, Beckmann JS, Sussman JL 2004 A paradigm for single nucleotide polymorphism analysis: the case of the acetylcholinesterase gene. Hum. Mutat. 24: 408-416. *

• Heresbach D, Gulwani-Akolkar B, Lesser M, Akolkar PN, Lin XY, Heresbach-Le Berre N, Bretagne JF, Katz S, Silver J 1998 Anticipation in Crohn's disease may be influenced by gender and ethnicity of the transmitting parent. Am. J. Gastroenterol. 93: 2368-2372. *

• Hodak E, Lapidoth M, Kohn K, David D, Brautbar B, Kfir K, Narinski N, Safirman S, Maron M, Klein K 2001 Mycosis fungoides: HLA class II associations among Ashkenazi and non-Ashkenazi Jewish patients. Br. J. Dermatol. 145: 974-980. *

• Ilan Y, Shouval D 1992 Primary biliary cirrhosis in Israel. Isr. J. Med. Sci. 28: 683-687.

• Israel S, Weinrib L, Weintrob N, Miller K, Brautbar C 2006 Distribution of the V281L mutation of the CYP21 gene in Israeli congenital adrenal hyperplasia patients and its association with HLA- B14. Pediatr. Endocrinol. Rev. 3 Suppl. 3: 447-450.

• Jaeger E, Webb E, Howarth K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittman A, Kemp Z, Sullivan K, Heinimann K, Lubbe S, Domingo E, Barclay E, Martin L, Gorman M, Chandler I, Vijayakrishnan J, Wood W, Papaemmanuil E, et al 2008 Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat. Genet. 40: 26-28. *

• Kantor R, Gershoni JM 1999 Distribution of the CCR5 gene 32-base pair deletion in Israeli ethnic groups. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20: 81-84.

• Karban A, Hartman C, Eliakim R, Waterman M, Nesher S, Barnett-Griness O, Shamir R 2007 Paraoxonase (PON)1 192R allele carriage is associated with reduced risk of inflammatory bowel disease. Dig. Dis. Sci. 52: 2707-2715. *

• Karban A, Itay M, Davidovich O, Leshinsky-Silver E, Kimmel G, Fidder H, Shamir R, Waterman M, Eliakim R, Levine A 2007 Risk factors for perianal Crohn's disease: the role of genotype, phenotype, and ethnicity. Am. J. Gastroenterol. 102: 1702-1708. *

• Karban A, Waterman M, Panhuysen CI, Pollak RD, Nesher S, Datta L, Weiss B, Suissa A, Shamir R, Brant SR, Eliakim R 2004 NOD2/CARD15 genotype and phenotype differences between Ashkenazi and Sephardic jews with Crohn's disease. Am. J. Gastroenterol. 99: 1134-1140. *

• Karni A, Kohn Y, Safirman C, Abramsky O, Barcellos L, Oksenberg JR, Kahana E, Karussis D, Chapman J, Brautbar C 1999 Evidence for the genetic role of human leukocyte antigens in low frequency DRB1*1501 multiple sclerosis patients in Israel. Mult. Scler. 5: 410-415.

• Kerem B, Chiba-Falek O, Kerem E 1997 Cystic fibrosis in Jews: frequency and mutation distribution. Genet. Test. 1: 35-39.

• Kerem E, Kalman YM, Yahav Y, Shoshani T, Abeliovich D, Szeinberg A, Rivlin J, Blau H, Tal A, Ben-Tur L, et al 1995 Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel. Hum. Genet. 96: 193-197.

• Kerem E, Rave-Harel N, Augarten A, Madgar I, Nissim-Rafinia M, Yahav Y, Goshen R, Bentur L, Rivlin J, Aviram M, Genem A, Chiba-Falek O, Kraemer MR, Simon A, Branski D, Kerem B 1997 A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am. J. Respir. Crit. Care Med. 155: 1914-1920.

• Klement E, Lysy J, Hoshen M, Avitan M, Goldin E, Israeli E 2008 Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study. Am. J. Gastroenterol. 103: 1775-1782. *

• Klitz W, Brautbar C, Schito AM, Barcellos LF, Oksenberg JR 2001 Evolution of the CCR5 Delta32 mutation based on haplotype variation in Jewish and Northern European population samples. Hum. Immunol. 62: 530-538.

• Kornreich R, Ekstein J, Edelmann L, Desnick RJ 2004 Premarital and prenatal screening for cystic fibrosis: experience in the Ashkenazi Jewish population. Genet. Med. 6: 415-420.

• Kundhal KK, Kundhal PS, Griffiths AM 2001 Crohn’s disease in children. University of Toronto Medical Journal 78: 200-204. *

• Kutler D, Auerbach A 2004 Fanconi anemia in Ashkenazi Jews. Fam. Cancer 3: 241-248. *

• Kwon OJ, Brautbar C, Weintrob N, Sprecher E, Saphirman C, Bloch K, Pinhas-Hamiel O, Assah S, Vardi P, Israel S 2001 Immunogenetics of HLA class II in Israeli Ashkenazi Jewish, Israeli non-Ashkenazi Jewish, and in Israeli Arab IDDM patients. Hum. Immunol. 62: 85-91.

• Kwon OJ, Karni A, Israel S, Brautbar C, Amar A, Meiner Z, Abramsky O, Karussis D 1999 HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch. Neurol. 56: 555-560. *

• Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E 2007 Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. Isr. Med. Assoc. J. 9: 791-796.

• Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Abbott WG, Krissansen GW 2005 Polymorphisms of CARD15/NOD2 and CD14 genes in New Zealand Crohn’s disease patients. Immunol. Cell Biol. 83: 498-503. *

• Levine J, Furne JK, Levitt MD 1996 Ashkenazi Jews, sulfur gases, and ulcerative colitis. J. Clin. Gastroenterol. 22: 288-291.

• Locker GY, Kaul K, Weinberg DS, Gatalica Z, Gong G, Peterman A, Lynch J, Klatzco L, Olopade OI, Bomzer CA, Newlin A, Keenan E, Tajuddin M, Knezetic J, Coronel S, Lynch HT 2006 The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet. Cytogenet. 169: 33-38.

• Locker GY, Lynch HT 2004 Genetic factors and colorectal cancer in Ashkenazi Jews. Fam. Cancer 3: 215-221. *

• Lucotte G, Mercier G, Smets P 1999 Elevated frequencies of the mutant allele delta32 at the CCR5 gene in Ashkenazic Jews. AIDS Res. Hum. Retroviruses 15: 1-2. *

• Lucotte G, Smets P 2003 CCR5-Delta32 allele frequencies in Ashkenazi Jews. Genet. Test. 7: 333-337. *

• Lynch HT, Brand RE, Locker GY 2004 Inflammatory bowel disease in Ashkenazi Jews: implications for familial colorectal cancer. Fam. Cancer 3: 229-232. *

• Lynch HT, Deters CA, Lynch JF, Brand RE 2004 Familial pancreatic carcinoma in Jews. Fam. Cancer 3: 233-240. *

• Lynch HT, Rubinstein WS, Locker GY 2004 Cancer in Jews: introduction and overview. Fam. Cancer 3: 177-192. *

• Maayan S, Zhang L, Shinar E, Ho J, He T, Manni N, Kostrikis LG, Neumann AU 2000 Evidence for recent selection of the CCR5-delta 32 deletion from differences in its frequency between Ashkenazi and Sephardi Jews. Genes Immun. 1: 358-361. *

• Mack R, Chowdary D, Samaan P, Podolak I, Dermody J 2001 Prevalence of CTLA-4 polymorphism A49G in Ashkenazi Jews. Genet. Test. 5: 269-271.

• Martinez-Laso J, Gazit E, Gomez-Casado E, Morales P, Martinez-Quiles N, Alvarez M, Martin-Villa JM, Fernandez V, Arnaiz-Villena A 1996 HLA DR and DQ polymorphism in Ashkenazi and non-Ashkenazi Jews: comparison with other Mediterraneans. Tissue Antigens 47: 63-71.

• Mattit H, Joma M, Al-Cheikh S, El-Khateeb M, Medlej-Hashim M, Salem N, Delague V, Megarbane A 2006 Familial Mediterranean fever in the Syrian population: gene mutation frequencies, carrier rates and phenotype-genotype correlation. Eur. J. Med. Genet. 49: 481-486.

• Medlej-Hashim M, Loiselet J, Lefranc G, Megarbane A 2004 Familial Mediterranean Fever (FMF): from diagnosis to treatment. Sante. 14: 261-266.

• Mikula M, Buller A, Sun W, Strom CM 2008 Prevalence of known mutations in the familial Mediterranean fever gene (MEFV) in various carrier screening populations. Genet. Med. 10: 349-352.

• Mimouni D, Bar H, Gdalevich M, Katzenelson V, David M 2008 Pemphigus - analysis of epidemiological factors in 155 patients. J. Eur. Acad. Dermatol. Venereol. May 12 [Epub ahead of print]. *

• Mitra N, Ye TZ, Smith A, Chuai S, Kirchhoff T, Peterlongo P, Nafa K, Phillips MS, Offit K, Ellis NA 2004 Localization of cancer susceptibility genes by genome-wide single-nucleotide polymorphism linkage-disequilibrium mapping. Cancer Res. 64: 8116-8125. *

• Mor-Cohen R, Zivelin A, Rosenberg N, Goldberg I, Seligsohn U 2005 A novel ancestral splicing mutation in the multidrug resistance protein 2 gene causes Dubin-Johnson syndrome in Ashkenazi Jewish patients. Hepatol. Res. 31: 104-111.

• Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J 2002 Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J. Rheumatol. 29: 2379-2381.

• Nebel A, Filon D, Faerman M, Soodyall H, Oppenheim A 2005 Y chromosome evidence for a founder effect in Ashkenazi Jews. Eur. J. Hum. Genet. 13: 388-391. *

• Newman B, Silverberg MS, Gu X, Zhang Q, Lazaro A, Steinhart AH, Greenberg GR, Griffiths AM, McLeod RS, Cohen Z, Fernandez-Vina M, Amos CI, Siminovitch K 2004 CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. Am. J. Gastroenterol. 99: 306-315. *

• Newman WG, Gu X, Wintle RF, Liu X, van Oene M, Amos CI, Siminovitch KA 2006 DLG5 variants contribute to Crohn disease risk in a Canadian population. Hum. Mutat. 27: 353-358.

• Niv Y, Abuksis G, Fraser GM 2000 Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am. J. Gastroenterol. 95: 693-698. *

• Ohmen JD, Yang HY, Yamamoto KK, Zhao HY, Ma Y, Bentley LG, Huang Z, Gerwehr S, Pressman S, McElree C, Targan S, Rotter JI, Fischel-Ghodsian N 1996 Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis. Hum. Mol. Genet. 5: 1679-1683. *

• Oostenbrug LE, van Dullemen HM, te Meerman GJ, Jansen PL 2003 IBD and genetics: new developments. Scand. J. Gastroenterol. Suppl. 239: 63-68. *

• Orgad S, Neumann S, Loewenthal R, Netanelov-Shapira I, Gazit E 2001 Prevalence of cystic fibrosis mutations in Israeli Jews. Genet. Test. 5: 47-52.

• Ostrovsky O, Nagler A, Korostishevsky M, Gazit E, Galski H 2004 Genotype and allele frequencies of C3435T polymorphism of the MDR1 gene in various Jewish populations of Israel. Ther. Drug Monit. 26: 679-684.

• Palomaki GE, FitzSimmons SC, Haddow JE 2004 Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genet. Med. 6: 405-414.

• Panhuysen CI, Karban A, Knodle Manning A, Bayless TM, Duerr RH, Bailey-Wilson JE, Epstein EH Jr, Brant SR 2006 Identification of genetic loci for basal cell nevus syndrome and inflammatory bowel disease in a single large pedigree. Hum. Genet. 120: 31-41. *

• Permutt MA, Wasson JC, Suarez BK, Lin J, Thomas J, Meyer J, Lewitzky S, Rennich JS, Parker A, DuPrat L, Maruti S, Chayen S, Glaser B 2001 A genome scan for type 2 diabetes susceptibility loci in a genetically isolated population. Diabetes 50: 681-685. *

• Quint A, Lerer I, Sagi M, Abeliovich D 2005 Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. Am. J. Med. Genet. 136A: 246-248.

• Rady PL, Tyring SK, Hudnall SD, Vargas T, Kellner LH, Nitowsky H, Matalon RK 1999 Methylenetetrahydrofolate reductase (MTHFR): the incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. Am. J. Med. Genet. 86: 380-384. *

• Rennert G, Almog R, Tomsho LP, Low M, Pinchev M, Chaiter Y, Bonner JD, Rennert HS, Greenson JK, Gruber SB 2005 Colorectal polyps in carriers of the APC I1307K polymorphism. Dis. Colon Rectum 48: 2317-2321. *

• Risch N, Tang H, Katzenstein H, Ekstein J 2003 Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection. Am. J. Hum. Genet. 72: 812-822. *

• Robles-Diaz L, Goldfrank D, Kauff N, Robson M, Offit K 2004 Hereditary ovarian cancer in Ashkenazi Jews. Fam. Cancer 3: 259-264. *

• Roitberg-Tambur A, Witt CS, Friedmann A, Safirman C, Sherman L, Battat S, Nelken D, Brautbar C 1995 Comparative analysis of HLA polymorphism at the serologic and molecular level in Moroccan and Ashkenazi Jews. Tissue Antigens 46: 104-110.

• Rubinstein W 2004 Hereditary breast cancer in Jews. Fam. Cancer 3: 249-257. *

• Sandhu MS, Weedon MN, Fawcett KA, Wasson J, Debenham SL, Daly A, Lango H, Frayling TM, Neumann RJ, Sherva R, Blech I, Pharoah PD, Palmer CN, Kimber C, Tavendale R, Morris AD, McCarthy MI, Walker M, Hitman G, Glaser B, Permutt MA, Hattersley AT, et al 2007 Common variants in WFS1 confer risk of type 2 diabetes. Nat. Genet. 39: 951-953. *

• Sandler RS, Golden AL 1986 Epidemiology of Crohn's disease. J. Clin. Gastroenterol. 8: 160-165.

• Scott SA, Edelmann L, Kornreich R, Erazo M, Desnick RJ 2008 CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics 8: 721-730.

• Scully C, Mignogna M 2008 Oral mucosal disease: pemphigus. Br. J. Oral Maxillofac. Surg. 46: 272-277.

• Sereth H, Shoshani T, Bashan N, Kerem BS 1993 Extended haplotype analysis of cystic fibrosis mutations and its implications for the selective advantage hypothesis. Hum. Genet. 92: 289-295.

• Shinar Y, Livneh A, Villa Y, Pinhasov A, Zeitoun I, Kogan A, Achiron A 2003 Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Ashkenazi Jewish multiple sclerosis patients. Genes Immun. 4: 197-203. *

• Shmuely H, Samra Z, Ashkenazi S, Dinari G, Chodick G, Yahav J 2004 Association of Helicobacter pylori infection with Shigella gastroenteritis in young children. Am. J. Gastroenterol. 99: 2041-2045. *

• Shpilberg O, Peretz H, Zivelin A, Yatuv R, Chetrit A, Kulka T, Stern C, Weiss E, Seligsohn U 1995 One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 85: 429-432. *

• Shtoyerman-Chen R, Friedman E, Figer A, Carmel M, Patael Y, Rath P, Fidder HH, Bar-Meir S, Theodor L 2001 The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect. Genet. Test. 5: 141-146.

• Shugart YY, Silverberg MS, Duerr RH, Taylor KD, Wang MH, Zarfas K, Schumm LP, Bromfield G, Steinhart AH, Griffiths AM, Kane SV, Barmada MM, Rotter JI, Mei L, Bernstein CN, Bayless TM, Langelier D, Cohen A, Bitton A, Rioux JD, Cho JH, Brant SR 2008 An SNP linkage scan identifies significant Crohn's disease loci on chromosomes 13q13.3 and, in Jewish families, on 1p35.2 and 3q29. Genes Immun. 9: 161-167. *

• Silbermintz A, Levine J, Weinstein T, Silver J 2008 Polymorphisms in the tumor necrosis factor/lipopolysaccharides pathway in Crohn disease in the Jewish Ashkenazi population. J. Pediatr. Gastroenterol. Nutr. 46: 546-550.

• Silverberg MS, Clelland C, Murphy JE, Steinhart AH, McLeod RS, Greenberg GR, Cohen Z, Siminovitch KA 2001 Carrier rate of APC I1307K is not increased in inflammatory bowel disease patients of Ashkenazi Jewish origin. Hum. Genet. 108: 205-210. *

• Silverberg MS, Duerr RH, Brant SR, Bromfield G, Datta LW, Jani N, Kane SV, Rotter JI, Philip Schumm L, Hillary Steinhart A, Taylor KD, Yang H, Cho JH, Rioux JD, Daly MJ 2007 Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease. Eur. J. Hum. Genet. 15: 328-335. *

• Starinsky S, Figer A, Ben-Asher E, Geva R, Flex D, Fidder HH, Zidan J, Lancet D, Friedman E 2005 Genotype phenotype correlations in Israeli colorectal cancer patients. Int. J. Cancer 114: 58-73. *

• Strom CM, Crossley B, Redman JB, Quan F, Buller A, McGinniss MJ, Sun W 2004 Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory. Genet. Med. 6: 145-152.

• Sugimura K, Taylor KD, Lin YC, Hang T, Wang D, Tang YM, Fischel-Ghodsian N, Targan SR, Rotter JI, Yang H 2003 A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am. J. Hum. Genet. 72: 509-518. *

• Tighe MR, Hall MA, Ashkenazi A, Siegler E, Lanchbury JS, Ciclitira PJ 1993 Celiac disease among Ashkenazi Jews from Israel. A study of the HLA class II alleles and their associations with disease susceptibility. Hum. Immunol. 38: 270-276.

• Tighe MR, Hall MA, Cardi E, Ashkenazi A, Lanchbury JS, Ciclitira PJ 1994 Associations between alleles of the major histocompatibility complex-encoded ABC transporter gene TAP2, HLA class II alleles, and celiac disease susceptibility. Hum. Immunol. 39: 9-16.

• Trachtenberg EA, Yang H, Hayes E, Vinson M, Lin C, Targan SR, Tyan D, Erlich H, Rotter JI 2000 HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations. Hum. Immunol. 61: 326-333.

• Tukel T, Shalata A, Present D, Rachmilewitz D, Mayer L, Grant D, Risch N, Desnick RJ 2004 Crohn disease: frequency and nature of CARD15 mutations in Ashkenazi and Sephardi/Oriental jewish families. Am. J. Hum. Genet. 74: 623-636. *

• Tunca M, Ozdogan H 2005 Molecular and genetic characteristics of hereditary autoinflammatory diseases. Curr. Drug Targets Inflamm. Allergy 4: 77-80.

• Vaxillaire M, Dina C, Lobbens S, Dechaume A, Vasseur-Delannoy V, Helbecque N, Charpentier G, Froguel P 2005 Effect of common polymorphisms in the HNF4alpha promoter on susceptibility to type 2 diabetes in the French Caucasian population. Diabetologia 48: 440-444. *

• Venken T, Alaerts M, Souery D, Goossens D, Sluijs S, Navon R, Van Broeckhoven C, Mendlewicz J, Del-Favero J, Claes S 2008 Chromosome 10q harbors a susceptibility locus for bipolar disorder in Ashkenazi Jewish families. Mol. Psychiatry 13: 442-450.

• Weinstein LB 2007 Selected genetic disorders affecting Ashkenazi Jewish families. Fam. Community Health 30: 50-62.

• Weiss B, Shamir R, Bujanover Y, Waterman M, Hartman C, Fradkin A, Berkowitz D, Weintraub I, Eliakim R, Karban A 2004 NOD2/CARD15 mutation analysis and genotype-phenotype correlation in Jewish pediatric patients compared with adults with Crohn's disease. J. Pediatr. 145: 208-212. *

• Wijsman EM 1984 Techniques for estimating genetic admixture and applications to the problem of the origin of the Icelanders and the Ashkenazi Jews. Hum. Genet. 67: 441-448.

• Yang H, Ohmen JD, Ma Y, Bentley LG, Targan SR, Fischel-Ghodsian N, Rotter JI 1999 Additional evidence of linkage between Crohn's disease and a putative locus on chromosome 12. Genet. Med. 1: 194-198.

• Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ 2007 MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res. Treat. Nov 18 [Epub ahead of print].

• Zhou Z, Lin XY, Akolkar PN, Gulwani-Akolkar B, Levine J, Katz S, Silver J 2002 Variation at NOD2/CARD15 in familial and sporadic cases of Crohn's disease in the Ashkenazi Jewish population. Am. J. Gastroenterol. 97: 3095-3101. *

Number of references = 145

www psc-literature.org